Syntegra Private Wealth Group LLC Purchases 118 Shares of Abbott Laboratories (NYSE:ABT)

Syntegra Private Wealth Group LLC boosted its position in Abbott Laboratories (NYSE:ABT) by 0.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 12,693 shares of the healthcare product maker’s stock after buying an additional 118 shares during the quarter. Syntegra Private Wealth Group LLC’s holdings in Abbott Laboratories were worth $1,397,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Fairfield Bush & CO. purchased a new position in Abbott Laboratories in the 1st quarter worth about $131,000. United Bank raised its position in Abbott Laboratories by 7.2% in the 1st quarter. United Bank now owns 27,280 shares of the healthcare product maker’s stock worth $3,229,000 after buying an additional 1,826 shares during the last quarter. Mackenzie Financial Corp raised its position in Abbott Laboratories by 1.9% in the 1st quarter. Mackenzie Financial Corp now owns 813,253 shares of the healthcare product maker’s stock worth $96,257,000 after buying an additional 15,521 shares during the last quarter. Kinneret Advisory LLC raised its position in Abbott Laboratories by 2.3% in the 1st quarter. Kinneret Advisory LLC now owns 19,467 shares of the healthcare product maker’s stock worth $2,304,000 after buying an additional 436 shares during the last quarter. Finally, Lumature Wealth Partners LLC raised its position in Abbott Laboratories by 636.2% in the 1st quarter. Lumature Wealth Partners LLC now owns 2,216 shares of the healthcare product maker’s stock worth $262,000 after buying an additional 1,915 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrea F. Wainer sold 12,500 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total value of $1,500,000.00. Following the transaction, the executive vice president now directly owns 78,704 shares in the company, valued at approximately $9,444,480. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,435 shares of company stock worth $6,451,298. Company insiders own 1.10% of the company’s stock.

Abbott Laboratories Trading Up 0.1 %

NYSE:ABT traded up $0.16 during midday trading on Thursday, hitting $113.64. 5,278,016 shares of the company traded hands, compared to its average volume of 5,747,185. The firm’s fifty day moving average is $115.13 and its 200-day moving average is $106.42. Abbott Laboratories has a 12-month low of $89.67 and a 12-month high of $121.64. The firm has a market capitalization of $197.19 billion, a P/E ratio of 34.94, a P/E/G ratio of 2.68 and a beta of 0.75. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share for the quarter, meeting the consensus estimate of $1.19. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The company had revenue of $10.24 billion for the quarter, compared to analyst estimates of $10.19 billion. During the same quarter in the prior year, the firm posted $1.03 EPS. Abbott Laboratories’s quarterly revenue was up 1.5% compared to the same quarter last year. On average, sell-side analysts predict that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, April 12th. This represents a $2.20 annualized dividend and a yield of 1.94%. Abbott Laboratories’s payout ratio is presently 67.48%.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of recent research reports. Raymond James boosted their price target on Abbott Laboratories from $124.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, January 25th. Citigroup boosted their price target on Abbott Laboratories from $123.00 to $126.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b-” rating in a research note on Thursday, December 21st. Royal Bank of Canada reiterated an “outperform” rating and set a $128.00 price objective on shares of Abbott Laboratories in a research note on Wednesday, February 14th. Finally, Wells Fargo & Company boosted their price target on Abbott Laboratories from $116.00 to $121.00 and gave the stock an “overweight” rating in a report on Wednesday, December 13th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.